A new product appeared in the product portfolio of AKRIKHIN – Metozoc (INN - metoprolol succinate) for treatment of cardiovascular diseases. The product is developed by the Company R&D. It is the first generic of metoprolol succinate on the Russian market which has been created based on the technology applied in the original product. The product is included in the List of Essential Medicines.

According to the Ministry of Public Health and Social Development of the Russian Federation, today the death rate of population from cardiovascular diseases in Russia takes the leading place among other reasons and equals 57%.Following the strategy of launching modern and efficient products, strongly sought-for by the Russian healthcare, Akrikhin extends its cardiovascular line with a new product Metozoc included in the List of Essential Medicines and intended for treatment of such cardiovascular diseases as arterial hypertension, chronic cardiac failure, coronary disease, heart rhythm disturbance, etc.

Metozoc is a selective beta-adrenergic blocking agent created with the use of the technology which ensures constant level of product concentration in blood. Owing to this the patient has to take the medicine only once a day, as contrasted with other metoprolol generics administered with similar indications twice a day.

Metozoc is produced in three dosages for peroral administration (25 mg, 50 mg, 100 mg), which allows the doctor to prescribe the most suitable dose for the patient. In addition, the price for Metozoc is 25-30% lower than the cost of the original product. The comfort of usage and the affordability are significant factors for patients with cardiovascular diseases forced to receive medical therapy permanently.

The cardiovascular line is one of the most important lines for Akrikhin. The portfolio of cardio medicines includes 15 products, 9 of which are developments of the Company R&D Centre.

About AKRIKHIN:

AKRIKHIN is one of the leading Russian pharmaceutical companies manufacturing high quality medicinal products, and one of the TOP 5 largest local pharmaceutical manufacturers in sales volume on the Russian pharmaceutical market.

AKRIKHIN was established in 1936. The product portfolio of the company includes over 150 medicines of the main pharmaceutical and therapeutic lines: cardiology, neurology, pediatrics, gynecology, dermatology, etc.

AKRIKHIN produces a wide range of socially significant medicines, being one of the largest Russian manufacturers of the products included in the List of Essential Medicines, and medicines against tuberculosis and diabetes.

Since 2007 Polpharma has been a strategic partner of AKRIKHIN on the Russian pharmaceutical market. Strategic partnership is based on close cooperation of the companies in the field of R&D, production and promotion of medicinal products. In 2011 Polpharma strengthened and extended the partnership by purchasing a majority stake in AKRIKHIN.

Based on the 2010 results AKRIKHIN became one of the TOP 3 most authoritative and influential Russian manufacturing pharmaceutical companies in the “Rating of Importance of Subjects of the Russian Pharmaceutical Market" (according to Pharmexpert data).

For additional information, please contact

Yulia Zaika, Public Relations Manager

AKRIKHIN

Phone (work): 8 (495) 721-36-97

Mobile: 8 (916) 839-95-71

E-mail: j.zaika@akrikhin.ru